



#5  
Pre  
B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ALDMANN *et al.*

Serial No.: 09/849,499

Filing Date: May 4, 2001

Atty Dkt: 1324.028

Group Art Unit: 1641

Examiner: Unassigned

Title: METHOD FOR PRODUCING  
DENDRITIC CELLS

Certificate of Mailing Under 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231, on October 5, 2001.

*Candice J. Clement*

Candice J. Clement  
Attorney for Applicants  
Reg. No. 39,946

Date of Signature: October 5, 2001

Assistant Commissioner for Patents  
Box Missing Parts  
Washington, D.C. 20231

SUPPLEMENTAL PRELIMINARY AMENDMENT UNDER 37 CFR 1.115

Dear Sir:

This paper is part of a Response to a Notice of Missing Parts mailed July 5, 2001 in connection with the above-captioned patent application. Prior to calculation of the filing fee, please amend the claims as follows:

**Amended Claims**

Please replace claims 81, 86 and 104 with the following:

B<sup>1</sup> 81. The process of claim 78, wherein the gene encodes FLIP or bcl-2.

B<sup>2</sup> 86. The process of claim 84, wherein the gene is a reporter gene which expresses a detectable product in the dendritic cells.

B<sup>3</sup> 104. The method of claim 98, wherein the immunotherapy comprises inducing a Th1 to Th2 immune deviation.